

Florence S H Wong

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2042540/florence-s-h-wong-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152
papers

9,166
citations

50
h-index

94
g-index

168
ext. papers

11,214
ext. citations

7.5
avg, IF

6.2
L-index

#	Paper	IF	Citations
152	Acute-on-Chronic Liver Failure Clinical Guidelines.. <i>American Journal of Gastroenterology</i> , 2022 , 117,	0.7	4
151	Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021 , 116, 336-346	0.7	2
150	Historical Aspects of Ascites and the Hepatorenal Syndrome. <i>Clinical Liver Disease</i> , 2021 , 18, 14-27	2.2	
149	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3612-3618	4	5
148	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1661-1669.e2	6.9	4
147	Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. <i>New England Journal of Medicine</i> , 2021 , 384, 818-828	59.2	55
146	Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort. <i>Liver Transplantation</i> , 2021 , 27, 1343-1347	4.5	8
145	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021 , 74, 1014-1048	11.2	45
144	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. <i>Hepatology</i> , 2021 , 74, 2699-2713	11.2	8
143	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 565-572.e5	6.9	3
142	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021 , 74, 330-339	13.4	20
141	Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. <i>Gut</i> , 2021 , 70, 531-536	19.2	94
140	REPLY. <i>Hepatology</i> , 2021 , 74, 2916-2917	11.2	
139	COVID-19 and Liver Cirrhosis: Focus on the Nonclassical Renin-Angiotensin System and Implications for Therapy. <i>Hepatology</i> , 2021 , 74, 1074-1080	11.2	3
138	The Prediction of In-Hospital Mortality in Decompensated Cirrhosis with Acute-on-Chronic Liver Failure. <i>Liver Transplantation</i> , 2021 ,	4.5	3
137	Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2021 , 75, 1010-1012	13.4	0
136	Reply. <i>Liver Transplantation</i> , 2020 , 26, 1541-1542	4.5	

135	Renal Dysfunction After Liver Transplantation: Effect of Donor Type. <i>Liver Transplantation</i> , 2020 , 26, 799-810	4.5	8
134	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2571-2579	4	5
133	Acute kidney injury: prediction, prognostication and optimisation for liver transplant. <i>Hepatology International</i> , 2020 , 14, 167-179	8.8	6
132	Model for End-Stage Liver Disease-Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. <i>Hepatology</i> , 2020 , 72, 1747-1757	11.2	20
131	Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump. <i>Liver Transplantation</i> , 2020 , 26, 651-661	4.5	10
130	Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. <i>Liver International</i> , 2020 , 40, 2385-2393	7.9	3
129	Management of Ascites 2020 , 11-30		
128	Latest Treatment of Acute Kidney Injury in Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2020 , 18, 281-294	2.5	1
127	Cirrhosis; Acute Kidney Injury 2020 , 514-525		
126	Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. <i>Liver International</i> , 2020 , 40, 18-31	7.9	22
125	Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. <i>Gastroenterology</i> , 2020 , 159, 1715-1730.e12	13.3	24
124	Feasibility and Procedural Safety of alfapump System Implantation by IR: Experience from the MOSAIC Study, a Multicenter, Open-Label Prospective Study in Cirrhotic Patients with Refractory Ascites. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 1256-1262.e3	2.4	1
123	Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1554-1561	4.3	11
122	Clinical Consequences of Infection in Cirrhosis: Organ Failures and Acute-on-Chronic Liver Failure. <i>Clinical Liver Disease</i> , 2019 , 14, 92-97	2.2	6
121	Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2339-2346.e1	6.9	10
120	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. <i>Liver Transplantation</i> , 2019 , 25, 870-880	4.5	22
119	Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever. <i>Hepatology</i> , 2019 , 70, 450-451	11.2	4
118	Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-Stage Liver Disease Experience. <i>Liver Transplantation</i> , 2019 , 25, 571-579	4.5	30

117	Refractory Ascites in Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 40-47	0.7	26
116	Reply. <i>Liver Transplantation</i> , 2019 , 25, 1586-1587	4.5	
115	Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis. <i>Nutrients</i> , 2019 , 11,	6.7	1
114	Ascites and Hepatorenal Syndrome. <i>Clinics in Liver Disease</i> , 2019 , 23, 659-682	4.6	9
113	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019 , 156, 1368-1380.e10	13.3	149
112	Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 599-606	0.7	8
111	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1091-1100	0.7	15
110	Treatment of Oesophageal Varices in Liver Cirrhosis. <i>Digestion</i> , 2019 , 99, 261-266	3.6	8
109	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 45-51	18.8	38
108	An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 293-305	4.2	13
107	Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 756-765.e3	6.9	50
106	Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C). <i>Antiviral Therapy</i> , 2019 , 24, 35-44	1.6	8
105	Utility of shear-wave elastography to differentiate low from advanced degrees of liver fibrosis in patients with hepatitis C virus infection of native and transplant livers. <i>Journal of Clinical Ultrasound</i> , 2018 , 46, 311-318	1	5
104	Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?. <i>Hepatology</i> , 2018 , 68, 1621-1632	11.2	65
103	Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. <i>American Journal of Gastroenterology</i> , 2018 , 113, 556-563	0.7	52
102	NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. <i>Hepatology</i> , 2018 , 67, 2367-2374	11.2	122
101	Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. <i>Liver International</i> , 2018 , 38, 1785-1792	7.9	7
100	The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1339	0.7	21

99	Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites 2018 , 38, 1785		1
98	Renal Failure in Cirrhosis 2018 , 262-280.e5		
97	Hepatorenal syndrome. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 23	51.1	82
96	Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 768-776	4	14
95	New diagnostic criteria and management of acute kidney injury. <i>Journal of Hepatology</i> , 2017 , 66, 860-861	13.4	22
94	Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 266-272.e1	6.9	30
93	Acute-on-Chronic Liver Failure 2017 , 432-459		
92	Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. <i>Gastroenterology</i> , 2016 , 150, 1579-1589.e2	13.3	141
91	Acute kidney injury in liver cirrhosis: new definition and application. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 415-422	6.9	44
90	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1821-1830.e6	6.9	46
89	The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. <i>Hepatology</i> , 2016 , 64, 200-8	11.2	137
88	Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 3084-3092	4	17
87	Diagnosing and treating renal disease in cirrhotic patients. <i>Minerva Gastroenterologica E Dietologica</i> , 2016 , 62, 253-66	1.6	8
86	Definition and Diagnosis of Acute Kidney Injury in Cirrhosis. <i>Digestive Diseases</i> , 2015 , 33, 539-47	3.2	6
85	Treatment to improve acute kidney injury in cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2015 , 13, 235-48	2.5	1
84	The evolving concept of acute kidney injury in patients with cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 711-9	24.2	28
83	Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 389-95	4	49
82	Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e1-5	2	16

81	Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 753-9.e1-2	6.9	81
80	Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. <i>Liver Transplantation</i> , 2015 , 21, 300-7	4.5	84
79	Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation. <i>Transplantation</i> , 2015 , 99, 1441-6	1.8	16
78	Variations in albumin use in patients with cirrhosis: An AASLD members survey. <i>Hepatology</i> , 2015 , 62, 1923-4	11.2	13
77	High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease. <i>Liver Transplantation</i> , 2015 , 21, 881-8	4.5	47
76	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015 , 64, 531-7	19.2	247
75	A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be. <i>Journal of Hepatology</i> , 2015 , 62, 741-3	13.4	23
74	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015 , 62, 968-74	13.4	391
73	Hepatorenal syndrome and acute kidney injury 2015 , 175-188		
72	Speckle tracking echocardiography in cirrhosis: is it ready for prime time?. <i>Hepatology International</i> , 2014 , 8, 10-3	8.8	
71	Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. <i>Hepatology</i> , 2014 , 60, 250-6	11.2	317
70	EASL Recognition Awardee for 2014: Prof. Tilman Sauerbruch. <i>Journal of Hepatology</i> , 2014 , 61, 469-71	13.4	
69	Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. <i>Metabolic Brain Disease</i> , 2013 , 28, 301-5	3.9	20
68	The impact of acute kidney injury in cirrhosis: does definition matter?. <i>Gut</i> , 2013 , 62, 1091-2	19.2	4
67	New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. <i>Gastroenterology</i> , 2013 , 145, 1280-8.e1	13.3	175
66	Acute kidney injury in decompensated cirrhosis. <i>Gut</i> , 2013 , 62, 131-7	19.2	165
65	Acute renal dysfunction in liver cirrhosis. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 830-2	0.7	2
64	Recent advances in our understanding of hepatorenal syndrome. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012 , 9, 382-91	24.2	70

63	Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. <i>Critical Care</i> , 2012 , 16, R23	10.8	106
62	Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. <i>Hepatology</i> , 2012 , 56, 2328-35	11.2	269
61	Bacterial infections in end-stage liver disease: current challenges and future directions. <i>Gut</i> , 2012 , 61, 1219-25	19.2	68
60	Management of ascites in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 11-20	4	54
59	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. <i>Gut</i> , 2012 , 61, 108-16	19.2	98
58	Renal diseases and the liver. <i>Clinics in Liver Disease</i> , 2011 , 15, 39-53	4.6	9
57	Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. <i>Gut</i> , 2011 , 60, 702-9	19.2	282
56	Medical management of ascites. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1269-83	4	8
55	Renal Complications of Liver Disease and the Hepatorenal Syndrome 2011 , 362-380		
54	Hepatorenal syndrome: do the vasoconstrictors work?. <i>Gastroenterology Clinics of North America</i> , 2011 , 40, 581-98	4.4	4
53	Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. <i>Liver International</i> , 2010 , 30, 937-47	7.9	120
52	Vaptans for Ascites [Chances and Risks. <i>Frontiers of Gastrointestinal Research</i> , 2010 , 91-101		
51	Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. <i>Gut</i> , 2010 , 59, 381-6	19.2	66
50	Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010 , 53, 283-90	13.4	74
49	Cirrhotic cardiomyopathy. <i>Hepatology International</i> , 2009 , 3, 294-304	8.8	130
48	The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2458-66	0.7	129
47	Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. <i>Hepatology</i> , 2008 , 47, 160-8	11.2	38
46	Hepatorenal syndrome: current management. <i>Current Gastroenterology Reports</i> , 2008 , 10, 22-9	5	9

45	Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. <i>Hepatology</i> , 2008 , 48, 204-13	11.2	157
44	Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <i>Postgraduate Medical Journal</i> , 2007 , 56, 1310-8	2	323
43	Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. <i>Gastroenterology</i> , 2007 , 133, 825-34	13.3	396
42	Drug insight: the role of albumin in the management of chronic liver disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007 , 4, 43-51		57
41	Portal hypertensive gastropathy. <i>Gastroenterology and Hepatology</i> , 2007 , 3, 428-73	0.7	3
40	The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. <i>Hepatology</i> , 2006 , 44, 640-9	11.2	4
39	Hyponatremia in cirrhosis: Results of a patient population survey. <i>Hepatology</i> , 2006 , 44, 1535-42	11.2	268
38	The use of TIPS in chronic liver disease. <i>Annals of Hepatology</i> , 2006 , 5, 5-15	3.1	30
37	The use of TIPS in chronic liver disease. <i>Annals of Hepatology</i> , 2006 , 5, 5-15	3.1	14
36	Management of Ascites 2005 , 301-317		
35	Hepatorenal syndrome: are we doing better?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2004 , 18, 121-2		
34	Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. <i>Hepatology</i> , 2004 , 40, 55-64	11.2	289
33	Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. <i>MedGenMed: Medscape General Medicine</i> , 2004 , 6, 9		3
32	Does losartan work after all?. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1222-4	0.7	2
31	The role of liver biopsy in the management of patients with liver disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003 , 17, 651-4		
30	A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. <i>Hepatology</i> , 2003 , 37, 182-91	11.2	213
29	The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. <i>Hepatology</i> , 2003 , 38, 258-66	11.2	554
28	The North American Study for the Treatment of Refractory Ascites. <i>Gastroenterology</i> , 2003 , 124, 634-41	13.3	334

27	The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. <i>Hepatology</i> , 2002 , 35, 1449-58	11.2	32
26	Excess nitric oxide in preascites: another piece in the puzzle. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2167-9	0.7	3
25	Liver and kidney diseases. <i>Clinics in Liver Disease</i> , 2002 , 6, 981-1011	4.6	13
24	Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. <i>Clinical Science</i> , 2001 , 101, 621-628	6.5	51
23	Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. <i>Clinical Science</i> , 2001 , 101, 621	6.5	16
22	New challenge of hepatorenal syndrome: prevention and treatment. <i>Hepatology</i> , 2001 , 34, 1242-51	11.2	58
21	The hyperdynamic circulation in cirrhosis: an overview 2001 , 89, 221-31		111
20	Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2442-7	0.7	73
19	The pathophysiologic basis for the treatment of cirrhotic ascites. <i>Clinics in Liver Disease</i> , 2001 , 5, 819-32	4.6	7
18	Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. <i>Hepatology</i> , 2000 , 31, 207-10	11.2	363
17	Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites ²² Part of this work was performed while holding a Fellowship in Hepatology from Schering Canada.. <i>American Journal of Medicine</i> , 1999 , 106, 315-322	2.4	50
16	Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homeostasis in cirrhotic patients with refractory ascites. <i>Clinical Science</i> , 1999 , 96, 467-474	6.5	6
15	Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. <i>Clinical Science</i> , 1999 , 97, 259-267	6.5	81
14	Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. <i>Clinical Science</i> , 1999 , 97, 259	6.5	29
13	The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. <i>Gastroenterology</i> , 1998 , 115, 397-405	13.3	33
12	Review: the controversy over the pathophysiology of ascites formation in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997 , 12, 437-44	4	13
11	Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. <i>Annals of Internal Medicine</i> , 1995 , 122, 816-22	8	170
10	Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. <i>Gastroenterology</i> , 1995 , 108, 1820-7	13.3	53

9	Systemic hemodynamic, forearm vascular, renal, and humoral responses to sustained cardiopulmonary baroreceptor deactivation in well-compensated cirrhosis. <i>Hepatology</i> , 1995 , 21, 717-724 ^{11.2}	2
8	Effects of sodium status on the venous response to noradrenaline infusion in pre-ascitic cirrhosis. <i>Clinical Science</i> , 1995 , 88, 525-31	6.5 7
7	Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. <i>Hepatology</i> , 1995 , 21, 1238-1247	11.2 272
6	Central blood volume in cirrhosis: Measurement with radionuclide angiography. <i>Hepatology</i> , 1994 , 19, 312-321	11.2 68
5	Renal response to a saline load in well-compensated alcoholic cirrhosis. <i>Hepatology</i> , 1994 , 20, 873-81	11.2 44
4	Central blood volume in cirrhosis: Measurement with radionuclide angiography 1994 , 19, 312	5
3	Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. <i>Gastroenterology</i> , 1993 , 104, 884-9	13.3 50
2	Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. <i>Hepatology</i> , 1993 , 18, 519-528	11.2 17
1	Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation 1993 , 18, 519	1